Research programme: antiviral therapeutics - SIGA

Drug Profile

Research programme: antiviral therapeutics - SIGA

Alternative Names: ST-148; ST-193; ST-294; ST-383; ST-610; ST-669

Latest Information Update: 23 Sep 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SIGA Technologies
  • Class Benzimidazoles; Small molecules
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Bunyavirus infections; Dengue; Ebola virus infections; Junin virus infections; Lassa fever; Marburg virus disease; Viral infections

Most Recent Events

  • 24 Aug 2011 SIGA technologies receives grant from National Institutes of Health (NIH) for antiviral drug development in Lassa fever and other haemorrhagic fevers of Arenavirus origin
  • 25 Feb 2010 SIGA Technologies receives funding from the US Department of Defense for ST 669 development in Viral infections
  • 25 Feb 2010 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top